EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Cyclosporine versus placebo pretreatment of brain-dead donors and kidney graft function (Cis-A-Rein trial): a multicenter, double-blind, randomized, controlled trial

Carole Ichai iD, Eric Fontaine, Karine Baumstarck, Thomas Rimmelé, Guillaume Strecker, Mohamed Boucekine, Vivien Szabo, Clément Gosset, Anne-Elisabeth Heng, Thomas Kerforne, Edouard Naboulsi, Lionel Velly und 11 weitere

Intensive Care Medicine · 2026

DOI: 10.1007/s00134-025-08265-6 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Intensive Care Medicine, 2026. Verfasst von Carole Ichai und 22 weiteren Autor:innen. Beteiligte Einrichtung: University of Côte d'Azur, Anesthesia and Critical Care Department, Pasteur 2, University of Nice, Nice, France. carole.ichai@univ-cotedazur.fr. Hauptthemen laut MEDLINE: Cyclosporine, Kidney Transplantation, Brain Death, Delayed Graft Function. Die Arbeit nennt 36 Literaturangaben. Gefördert von: French Ministry of health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Delayed graft function is the most frequent early complication of kidney transplantation. Pretreatment of kidney donors with cyclosporine has decreased delayed graft function in animal studies by reducing ischemia-reperfusion graft injuries. No randomized clinical trials have assessed the efficacy of cyclosporine pretreatment of brain-dead donors in reducing delayed graft function. METHODS: In this multicenter randomized, double-blind, and placebo-controlled trial, brain-dead donors were randomized (1:1) to receive either 2.5 mg/kg of cyclosporine or a glucose placebo infusion. The kidney transplant candidates were allocated through their donor assignment. The primary outcome was the occurrence of delayed graft function (DGF), defined as the need for at least one hemodialysis within the 7 days after kidney transplantation. Secondary outcomes included early graft function parameters within the 7 days post-transplantation, and 1-year graft and recipient survival. RESULTS: Between December 17, 2017 and March 3, 2023, 258 donors/331 recipients in the placebo group and 238 donors/312 recipients in the cyclosporine group were included in the modified intention-to-treat analysis. DGF occurred in 46 recipients (13.9%) in the placebo group and in 53 recipients (17.0%) in the cyclosporine group (unadjusted odd ratio = 1·27, 95% CI 0.83-1.95, P = 0.28). No significant between-group differences in the secondary outcomes (early graft function and 1-year graft and recipient survival) were observed. CONCLUSION: In this double-blind, randomized controlled clinical trial, a pretreatment of brain-dead donors with a single low dose of cyclosporine did not significantly reduce the occurrence of DGF in kidney transplant recipients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclosporineKidney TransplantationBrain DeathDelayed Graft FunctionTissue DonorsHumansDouble-Blind MethodFemaleMaleMiddle AgedAdultImmunosuppressive AgentsGraft Survival

Stichwörter der Autor:innen

Brain dead donorsCyclosporineDelayed graft functionKidney transplantation

Substanzen

CyclosporineImmunosuppressive Agents

Autor:innen und Institutionen

  • University of Côte d'Azur, Anesthesia and Critical Care Department, Pasteur 2, University of Nice, Nice, France. carole.ichai@univ-cotedazur.fr.
  • Research Unit INSERM U1055 LBFA, University Hospital of Grenoble, University of Grenoble Alpes, Grenoble, France.
  • Clinical Research Unit, Epidemiology and Health Economics Department, University Hospital of Marseille, University of Marseille Méditerranée, Marseille, France.
  • Anesthesia and Critical Care Department, Edouard Herriot, University of Lyon, Lyon, France.
  • Emergency and Trauma Care Unit, Organ and Tissue Procurement and Transplantation Network, University of Lille, Lille, France.
  • Research Unit EA 3279: Study and Research Center for Healthcare and Quality of Life Services (CEReSS), Marseille, France.

ORCID-Profile: Carole Ichai

Förderung

  • French Ministry of health

Zitieren

APA

Ichai, C., Fontaine, E., Baumstarck, K., Rimmelé, T., Strecker, G., Boucekine, M., Szabo, V., Gosset, C., Heng, A. E., Kerforne, T., Naboulsi, E., Velly, L., Leone, M., Pottecher, J., Dépret, F., Margetis, D., Bouhemad, B., Orban, J. C., Leroy, A., …, & Cis-A-Rein Group (2026). Cyclosporine versus placebo pretreatment of brain-dead donors and kidney graft function (Cis-A-Rein trial): a multicenter, double-blind, randomized, controlled trial. Intensive Care Medicine. https://doi.org/10.1007/s00134-025-08265-6

Vancouver

Ichai C, Fontaine E, Baumstarck K, Rimmelé T, Strecker G, Boucekine M, et al. Cyclosporine versus placebo pretreatment of brain-dead donors and kidney graft function (Cis-A-Rein trial): a multicenter, double-blind, randomized, controlled trial. Intensive Care Medicine. 2026. doi:10.1007/s00134-025-08265-6

BibTeX
@article{Ichai2026,
  author = {Ichai, Carole and Fontaine, Eric and Baumstarck, Karine and Rimmelé, Thomas and Strecker, Guillaume and Boucekine, Mohamed and Szabo, Vivien and Gosset, Clément and Heng, Anne-Elisabeth and Kerforne, Thomas and Naboulsi, Edouard and Velly, Lionel and Leone, Marc and Pottecher, Julien and Dépret, François and Margetis, Dimitri and Bouhemad, Bélaïd and Orban, Jean-Christophe and Leroy, Audrey and Riou, Bruno and Borao, Lucile and Constantin, Jean-Michel and Cis-A-Rein Group, Cis-A-Rein Group},
  title = {Cyclosporine versus placebo pretreatment of brain-dead donors and kidney graft function (Cis-A-Rein trial): a multicenter, double-blind, randomized, controlled trial},
  journal = {Intensive Care Medicine},
  year = {2026},
  doi = {10.1007/s00134-025-08265-6}
}
Kostenlos starten →